The Insight Partners Latest Research on “Hematuria Treatment Market Forecast to 2028″ Includes COVID-19 Impact and Global Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), and End User (Hospitals, Clinics, and ASC’s and Others) and Geography
Hematuria Treatment Market is projected to reach US$ 1,103.61 million by 2028 from US$ 932.89 million in 2021; it is expected to grow at a CAGR of 2.4% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Download PDF Sample Copy at: https://www.theinsightpartners.com/sample/TIPRE00004601/
Hematuria is the presence of blood in the urine. Blood can sometimes be found in the urine but is difficult to see; this is known as microscopic hematuria since it can only be seen under a microscope. The need for hematuria treatment has increased as the incidence of chronic renal disease and urinary tract infections has increased. High prevalence of hematuria-associated indications and increasing awareness about treatment options and improving healthcare expenditure are expected to boost the market growth.
Market Companies Analysis:
Market leaders operating in the market have undertaken various organic growth strategies in the hematuria treatment market. The hematuria treatment market majorly consists of the players AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaboration.
Below is the list of the growth strategies done by the players operating in the hematuria treatment market:
Sept-21: The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility
April-21: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC)
Inquire about Discount: https://www.theinsightpartners.com/discount/TIPRE00004601/
Feb-21: New State-of-the-Art Cell Therapy Manufacturing Facility Under Construction to Expand Bristol Myers Squibb Global Footprint
Oct-21: New Consumer Healthcare company headquarters to be based in Weybridge, UK The proposals announced to form part of GSK’s ongoing work to prepare for the separation of the Group into two leading UK-based companies next year – new GSK, a global pharmaceuticals and vaccines company with an R&D approach focused on the science of the immune system, human genetics and advanced technologies
Based on treatment, the hematuria treatment market is segmented into drugs, therapies, and others. The drugs segment held the largest share of the market in 2020. The increasing awareness about treatment options and improving healthcare expenditure are among the major factors boosting the market growth of the segment. Further, the market for the drugs segment is expected to grow at the highest CAGR during 2021–2028.
Hematuria treatment market, based on type, has been segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. The macroscopic hematuria segment is likely to hold the largest share of the market in 2021. However, the microscopic hematuria segment is anticipated to register the highest CAGR in the market during the forecast period.
Buy Report at: https://www.theinsightpartners.com/buy/TIPRE00004601/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi